

1 **Title:** Evolutionary engineering improves tolerance towards jet fuel replacements in yeast

2

3 **Authors:** Timothy C. R. Brennan¹, Thomas C. Williams¹, Benjamin L. Schulz³, Robin W.

4 Palfreyman¹, Jens O. Krömer^{2*}, Lars K. Nielsen¹

5

6 **Affiliations:**

7 1. Australian Institute for Bioengineering and Nanotechnology, University of

8 Queensland, Brisbane, Queensland, Australia

9 2. Centre for Microbial Electrosynthesis (CEMES), Advanced Water Management

10 Centre (AWMC) University of Queensland, Brisbane, Queensland, Australia

11 3. School of Chemistry and Molecular Biosciences, The University of Queensland,

12 Brisbane, QLD, 4072, Australia

13

14 **Running title:** Tolerance engineering of monoterpenes in yeast

15

16 **Journal section:** Physiology

17

18 #Corresponding author: Jens O Krömer, Centre for Microbial Electrosynthesis (CEMES),

19 Advanced Water Management Centre (AWMC), University of Queensland, Brisbane Qld

20 4072, Australia. Fax: 61-7-3365-4726; E-mail: j.kromer@uq.edu.au.

21

22 **Key words:** evolutionary engineering, genome re-sequencing, tolerance, monoterpene, jet

23 fuel, *Saccharomyces cerevisiae*

24

25

26 **Abstract:** Monoterpenes are liquid hydrocarbons with applications ranging from flavor and
27 fragrance to replacement jet fuel. Their toxicity, however, presents a major challenge for
28 microbial synthesis. Here we evolved limonene tolerant yeast and sequenced six strains
29 across the 200 generation evolutionary time course. Mutations were found in the tricalbin
30 proteins Tcb2p and Tcb3p. Genomic reconstruction in the parent strain showed that
31 truncation of a single protein (tTcb3p¹⁻⁹⁸⁹), but not its complete deletion, was sufficient to
32 recover the evolved phenotype improving limonene fitness by nine-fold. tTcb3p¹⁻⁹⁸⁹
33 increased tolerance towards two other monoterpenes (β -pinene and myrcene) by 11- and 8-
34 fold, respectively, and tolerance towards the bio-jet fuel blend AMJ-700t (10% cymene, 50%
35 limonene, 40% farnesene) by 4-fold. tTcb3p¹⁻⁹⁸⁹ is the first example of successful engineering
36 of phase tolerance and creates opportunities for the production of the highly toxic C₁₀ alkenes
37 in yeast.

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52 **Introduction**

53 Monoterpenes are ten-carbon (C_{10}) terpenes derived from two five-carbon (C_5) isoprene units
54 (22). Traditionally used in the flavor and fragrance industry, monoterpenes, such as *d*-
55 limonene, are now also being sought after as precursors for light end components of “drop-
56 in” jet fuels (7). With the ability to convert simple sugars into a variety of enantiomerically
57 pure monoterpene products (16, 27, 35), microbial synthesis has the potential to overcome the
58 low yields, impurities and high-cost associated with conventional chemical synthesis or
59 extraction from biological tissues (10). The C_{15} sesquiterpene, farnesene, is currently
60 produced via yeast fermentation for diesel markets (34). Monoterpenes and sesquiterpenes
61 are both derived from the mevalonate pathway indicating that yeast has the potential to
62 provide sufficient carbon, redox power and energy to produce commercial quantities of
63 monoterpenes. Unlike sesquiterpenes, however, monoterpenes are highly toxic. In *S.*
64 *cerevisiae*, for example, limonene halts growth at 60 mg/l (7). As maximizing titers is an
65 absolute requirement for cost effective production (19), toxicity is a critical challenge facing
66 microbial monoterpene production and biotransformation (23).

67

68 Being oils, monoterpenes are sparingly soluble in water and cause phase rather than
69 molecular toxicity. Molecular toxicity is caused by water-soluble compounds partitioning
70 into the plasma membrane and interfering with membrane properties (38). Molecular toxicity
71 is proportional to a solvent's aqueous concentration and is at its maximum at a solvent's
72 solubility point (i.e., at membrane and water saturation) (6). Phase toxicity occurs beyond a
73 solvent's solubility and is defined as inhibition due to a distinct second phase (7). The
74 molecular mechanisms of phase toxicity remain poorly understood, but we demonstrated in *S.*
75 *cerevisiae* that limonene interferes with cell wall integrity rather than membranes (6).

76 Accordingly, rational strategies for alleviating toxicity, such as manipulation of membrane
77 fluidity or expression of membrane-bound solvent pumps, have failed to resolve this problem
78 (20).

79

80 In the past decade, adaptive laboratory evolution (ALE) (9, 32) has proven to be a successful
81 technique for identifying biological solutions to combat alcohol (2, 8) and organic acid (21,
82 43) toxicity. Here we used ALE to identify genetic targets to alleviate phase toxicity. We
83 describe a mutation in a single protein (tTcb3p¹⁻⁹⁸⁹) that can serve as a tool for the production
84 of monoterpenes beyond their inhibitory limits.

85

86 **Materials and Methods**

87 **Strains, media and chemicals**

88 The *Saccharomyces cerevisiae* strain S288C (*MATa SUC2 gal2 mal mel flo1 flo8-1 hap1*)
89 was used as the parental strain and provided by the Australian Wine Research Institute
90 (AWRI), Adelaide, South Australia, Australia. A list of all strains used in this study can be
91 found in Table S3. Knockout strains ($\Delta tcb3$ and $\Delta tcb2$) were derived from the BY4741 strain
92 deletion collection (17). Genotypes for $\Delta tcb3$ and $\Delta tcb2$ strains are: MATa; *his3 Δ 1*; *leu2 Δ 0*;
93 *met15 Δ 0*; *ura3 Δ 0*; *tcb3 Δ ::kanMX4* and similarly for $\Delta tcb2$ MATa; *his3 Δ 1*; *leu2 Δ 0*;
94 *met15 Δ 0*; *ura3 Δ 0*; *tcb2 Δ ::kanMX4*. All chemicals were purchased from Sigma-Aldrich and
95 were of analytical-grade. AMJ-700t was prepared in a 1 ml stock by mixing 50% v/v
96 limonene, 10%v/v cymene and 40% v/v farnesene. Unless otherwise noted, synthetic media
97 (CBS) consisted of 2 g/l sucrose, 5 g/l (NH₄)₂ SO₄, 3 g/l KH₂PO₄, 0.5 g/l MgSO₄·7H₂O, and
98 vitamins and trace metals described in (7). YPD solid medium consisted of 10 g/l yeast
99 extract, 10 g/l polypeptone and 20 g/l sucrose. LM is YPD medium containing 300 mg/l

100 limonene. CBS⁺ media was CBS but consisted of 5 g/l sucrose with the addition of 20 mg/l
101 uracil, 50 mg/l L-histidine, 50 mg/l L-methionine and 100 mg/l L-leucine.

102

103 **Adaptive evolution by serial batch passage**

104 The parental strain (S288C) was transferred from a glycerol stock stored at -80°C and grown
105 on solid YPD medium at 30°C. A single colony of the parent strain was used to inoculate 10
106 ml of CBS media and this pre-culture was grown overnight until the mid-exponential growth
107 phase. The appropriate volume from the pre-culture was used to inoculate 22 ml of CBS
108 media in 250 ml Teflon™-lined screw-top baffled shake flasks to a target OD₆₆₀ = 0.2. The
109 initial volume of limonene added to the culture at inoculation was 1.0 µl (38 mg/l). Limonene
110 was directly added to the culture aseptically using a 10 µL glass-syringe (Gerstel, Mulheim,
111 Germany) immediately after inoculation. The culture was then incubated at 30°C at 200 rpm
112 (Orbit 25 mm, Multitron, Infors, Bottmingen, Switzerland) until the cell density reached mid-
113 exponential phase (OD₆₆₀ ~ 1-2, corresponding to circa 3 doubling times) before they were
114 transferred. For the next round, the appropriate volume of the previous limonene-challenged
115 culture was used to inoculate fresh medium (22 ml) to a target OD₆₆₀ = 0.2. After several
116 transfers (2-4) at a given limonene load, the amount of limonene was increased (between 0.2
117 – 0.5 µl (7.6-19 mg/l) of additional limonene). After 52 daily sequential passages the final
118 limonene load was 5.8 µl (222 mg/l). After each passage, 0.5 ml of culture (in the presence of
119 limonene) was added to 0.5 ml of 40% v/v glycerol solution and the samples were stored at -
120 80°C.

121

122 **Screening mutants**

123 Mutants were screened by streaking frozen glycerol stocks out onto solid LM medium plates.
124 The largest single colonies (8-12) were subjected to a second competitive growth screen in

liquid CBS medium containing 95 mg/l of limonene. Isolates were pre-cultured in CBS medium (10 ml) overnight at 30°C (200 rpm) and the appropriate volume of the pre-culture was used to inoculate 22 ml of CBS to an $OD_{660} = 0.2$ in 250 ml Teflon™-sealed screw-top shake flasks. Then 2.5 μ l of limonene (95 mg/l) was added immediately after inoculation and growth was monitored for 12 h using a Libra S4 spectrophotometer at 660 nm. The mutant with the highest specific growth rate was chosen for tolerance testing.

131

132 **Tolerance test**

The evolved and un-evolved strains were evaluated for tolerance to each toxic compound as described in (7). Briefly, cultures were grown until mid-exponential phase ($\sim OD_{660} = 1.0$) and then dosed with varying amounts of solvent. The optical density was evaluated for the ensuing 6 h. The minimum inhibitory concentration (MIC) is defined as the amount of solvent required to inhibit the specific growth rate by approximately 50% compared to that of the control strain with no solvent present. For fitness tests, 3.6 μ l (138 mg/l) of limonene was added to the inoculum (22 ml at $OD_{660} = 0.2$) and growth was monitored as described above. The ratio of the OD_{660} at 12 and 0 h was used as a relative fitness metric for solvent tolerance (3). CBS medium containing 5 g/l sucrose was used in all tolerance tests (CBS⁺ medium was used for the $\Delta tcb3$ strain and fitness in the reconstructed tTcb3p, TB516, S288C and BY4741 strains was also tested in CBS⁺ medium, Table S7). All tolerance tests were performed in biological triplicate for each compound and strain.

145

146 **DNA isolation**

All DNA was isolated according to Otero *et al.* (31) with the following modifications. A total of 5 ml of culture was harvested in mid-log ($OD \sim 3$) (16,000 rcf, 25°C), washed twice with distilled water, pelleted, and re-suspended in 800 μ l of lysis buffer (1% SDS, 50 mM EDTA,

150 0.1 M TrisHCl, pH 7.5). The suspension was transferred to FastPrep screw cap tubes
151 containing 1 g of 0.5 μ m acid washed beads and 100 μ l of 5 M NaCl. To lyse the cells, four
152 bead-beating cycles (30 s of beating followed by 1 min on ice) were carried out in a
153 mechanical bead beater (John Morris Scientific, Pty Ltd., Sydney, Australia). The suspension
154 was then harvested (16,000 rcf, 4°C) for 15 min, and the resulting clear liquid (circa 800 μ l)
155 was transferred to new 1.5 ml extra-clean tubes (Mo Bio, Carlsbad, CA). Next, 777 μ l of a
156 chloroform:isoamyl alcohol (24:1) mixture was added and incubated at 25°C for 30 min with
157 gentle rocking. The mixture was then pelleted for 15 min (16,000 rcf, 25°C) and the top,
158 aqueous layer was transferred to a new extra-clean tube and mixed with 70% v/v isopropanol
159 and centrifuged (16,000 rcf, 25°C) for 6 min. The isopropanol suspension was decanted and
160 the pellet was re-suspended in 70% ethanol. The ethanol suspension was centrifuged (16,000
161 rcf, 25°C) for 6 min and the pellet was allowed to dry for 45 min. The pellet was re-
162 suspended in 50 μ l of DNA and RNA-free water containing 100 μ g/ml RNase A and
163 incubated at room temperature for 30 min.

164

165 **Genome sequencing**

166 Paired-end (100 bp) genomic DNA libraries were generated using TruSeq DNA Sample
167 Preparation Kits according to the manufactures instructions (Illumina, San Diego, CA).
168 Genomic DNA was sheared to a target insert size of 300-400 base pairs using a Cavaris
169 ultrasonicator (model M220, Cavaris Inc., Woburn, MA). Whole genome re-sequencing was
170 performed by the Queensland Centre for Medical Genomics (Institute for Molecular
171 Bioscience, University of Queensland, Australia) using an Illumina HiSEQ 2500 system
172 (HiSEQ Control Software 2.0.5, RTA 1.17.20) following the standard rapid sequencing
173 workflow of cluster generation and sequencing by synthesis. Initially, libraries were loaded
174 onto an Illumina cBot instrument for template hybridization and initial extension steps using

175 the TruSeq Rapid Duo cBot Sample Loading Kit (cat# CT-402-4001). Flowcells were then
176 moved to the HiSeq 2500 instrument to complete cluster generation and sequencing using
177 TruSeq Rapid Cluster Kit - Paired-End (cat# PE-402-4001) and TruSeq Rapid SBS Kits –
178 200 Cycle (cat# FC-402-4001) following the manufacturer's publications. Samples were
179 loaded at a concentration of 6pM and a total of 209 cycles of sequencing were completed
180 consisting of 2x 101bp reads and a single 7bp index sequence.

181

182 For mutation analysis, the default settings in Bowtie2 (v 2.0.2) and samtools (v 0.1.18) were
183 used in the alignment and mapping (24). The input paired-end reads (101 bp) were trimmed
184 based on quality (3 bases from the start and 23 bases from the end) to produce 75 bp reads for
185 each sample. The results from the mapping were used to identify single nucleotide
186 polymorphisms (SNPs) and insertions and deletions (INDELS) between the mutant and
187 reference strain. The initial sequencing results and mutations, which were identified
188 according to the default software settings mentioned above, are listed in Table S1. The
189 mutations in Table S1 were further filtered and alignments were viewed using the Integrative
190 Genomics Viewer (IGV) software (36). A mutation was only called if it met the following
191 criteria: the mutation occurred in a coding region and SNPs and INDELS were filtered using
192 a Phred-like consensus quality >30. For SNPs, the coverage depth was ≥ 10 and >95% of the
193 base pair reads harbored the mutation. For INDELS, some INDELS were filtered out if the
194 number of reads with INDELS was less than the number of reads without INDELS. For
195 example, initially 39 mutations were identified in evolved strain TB302, however, after
196 filtering only 10 mutations occurred in coding regions and 2 of them met the filtering criteria.
197 Annotation and prediction of the effects caused by the mutations was carried out using the
198 program snpEff (v 3.1) (13). The data was run against the ensemble build (EF4.68) of the
199 S288C reference genome and used as input in the snpEff database.

200

201 **Genomic reconstruction**

202 Introduction of the mutations, *PDR3* (Q763L) and *TCB3* (frame shift at 989), into the
203 parental strain (S288C) was carried out using the recyclable dominant marker cassette
204 *amdSYM* (39). Throughout the text, the reconstructed S288C strain harboring the truncation
205 mutation at position 989 in *TCB3* is referred to as tTcb3p. The details of the construction and
206 primers used can be found in the supplemental material (Table S2 and Table S8 for SNP
207 reconstruction efficiency). A gain-of-function assay was performed for all reconstructed
208 strains. As described above, the relative fitness towards limonene, cymene, β -pinene,
209 myrcene and AMJ-700t was investigated for the parental strain, evolved (TB516) and
210 reconstructed strains.

211

212 **Fluorochrome staining and flow cytometry**

213 For S288C and tTcb3p strains, cell viability and cell wall damage were assessed using the
214 vital staining dye propidium iodide (PI) and cell wall binding dye calcofluor white (CFW).
215 Briefly, cells were treated with an inhibitory amount of limonene (138 mg/l) during midlog
216 growth phase (20 g/l CBS media). After 2 h of treatment, cell viability (described in (7)) and
217 cell wall staining (described in (6)) were tested in biological triplicate.

218

219 **Transcriptomics**

220 Total RNA was isolated from S288C and tTcb3p cultures during mid-exponential growth
221 phase. For control (no limonene) and limonene challenged (107 mg/l) cultures as described
222 previously (6) approximately 10 ml of culture was quickly pelleted (17,572 rcf x g) for 2 min
223 at 4°C and then immediately re-suspended in 2 ml of RNeasy lysis solution (Life
224 Technologies, Carlsbad, CA) and stored at 4°C. The RiboPure-Yeast kit (Ambion, Life

Technologies, Carlsbad, CA) was used for total RNA extraction according to manufacturer's instructions except bead beating was used to lyse the cells as previously described in (6). The RNA quality was assessed using an Agilent 2100 Bioanalyzer and RNA 6000 Nano kit according to manufacturer's methods (Agilent, Santa Clara, CA). For the microarrays (Affymetrix yeast genome 2.0), samples were labeled with 100 ng of total RNA starting material and labeled using the Affymetrix IVT Express Labelling Assay, according to the manufacturer's instructions (Santa Clara, CA). For hybridization, 4 µg of fragmented biotin labelled cRNA was hybridized to each array at 45°C for 16 hours at 60 rpm in an Affymetrix hybridization oven. Arrays were washed according to the manufacturer's instructions using an Affymetrix GeneChip Fluidics Station 450. Arrays were scanned using an Affymetrix S3000 scanner. The entire microarray processing procedure was performed at the Ramaciotti Centre for Gene Function Analysis (University of New South Wales, Sydney, Australia). Analysis of differentially expressed genes and gene set analysis (GSA) was carried out in R using the default values in Piano (42). All analysis was performed in biological triplicate.

239

240 **Cell wall proteomics**

The total cell wall extracts were isolated for the parental strain S288C and tTcb3p¹⁻⁹⁸⁹ cultures during mid-exponential growth phase. Cultures were inoculated to a starting OD₆₆₀ = 0.1 in 22 ml of CBS (5 g/l sucrose) and allowed to grow until OD₆₆₀ = 1.0 in the absence and presence of limonene challenge (107 mg/l). Approximately 20 ml of culture was pelleted (4,025 rcf for 5 min at room temperature), washed with sterile water, snap frozen by quickly submerging the sample in dry ice for 2 min and stored at -80°C. Cell wall protein extraction followed the method previously described in (37). Briefly, yeast cells were lysed with a bead beater, insoluble cell wall material was stringently washed, N-glycans were released with EndoH and deglycosylated proteins covalently linked to the cell wall polysaccharide were

250 digested with trypsin. Peptides were desalted with C18 ZipTips (Millipore) and detected by
251 LC-ESI-MS/MS with a Prominence nanoLC system (Shimadzu) and TripleTof 5600 mass
252 spectrometer with a Nanospray III interface (AB SCIEX). For information dependent
253 acquisition (IDA), analyses were performed as described (4). Identical LC conditions were
254 used for SWATH-MS, with an MS-TOF scan from an m/z of 350-1800 for 0.05 s followed by
255 high sensitivity information independent acquisition with 26 m/z isolation windows with 1
256 m/z window overlap each for 0.1 s across an m/z range of 400-1250. The overall SWATH
257 (Sequential Window Acquisition of all Theoretical Mass Spectra) method was previously
258 described in (18) and has been successfully used for proteomic quantification in yeast and
259 other tissues without the use of wild-type vs. wild-type statistical comparisons (26, 40).
260 Collision energy was automatically assigned by the Analyst software (AB SCIEX) based on
261 m/z window ranges. Proteins were identified from IDA data using ProteinPilot (AB SCIEX)
262 as described (4). False discovery rate analysis using ProteinPilot was performed on all
263 searches. Peptides identified with greater than 99 % confidence and with a local false
264 discovery rate of less than 1 % were included for further analysis. *S. cerevisiae* cell wall
265 proteins identified in this discovery data were used as the spectral library for analysis of
266 SWATH MS/MS data using the SWATH processing script within PeakView 1.2 (AB
267 SCIEX). Fragment ion peak area was used for quantification. The software package MSstats
268 (11) was used for statistical analysis in R. Statistical significance cutoff was set at $p < 0.05$.
269 All data was performed in biological triplicate.

270 Sequencing, transcriptome and proteome data is available online

271 (<http://pathway.aibn.uq.edu.au/S288c/>).

272

273 **Results**

274 **Evolved mutants show improved tolerance towards limonene**

275 Serial batch passaging was used to isolate limonene-tolerant yeast strains. The parental

276 S288C strain underwent 52 daily sequential transfers under limonene stress. The limonene

277 load increased from 38 mg/l to 222 mg/l. Tolerant strains were isolated as single colonies on

278 plates during the adaptive evolution process and tested for limonene tolerance. Two strains

279 were isolated between 100-200 generations and 4 strains were isolated at 200 generations.

280 Two tests were used to examine the improved fitness. The minimum inhibitory concentration

281 (MIC in Table 1 and Fig. S1) and relative fitness (Fig. 1) were measured for each strain and

282 compared to the parent. Relative fitness was defined as the ratio of the cell density (OD660)

283 at 12 hr to 0 hr under limonene exposure. All of the evolved strains showed at least a 1.9-fold

284 improvement in the MIC (Table 1) and at least a 9-fold improvement in the relative fitness

285 for limonene (Fig. 1). The maximum relative fitness score (10.9 ± 1.6) was achieved at 120

286 generations (strain TB302) and did not significantly improve for later generations (160-200 in

287 Fig. 1). In the absence of limonene, the maximum fitness score was 23.4 ± 0.4 . For all strains

288 and all tolerance tests, cell viability remained above 90% after 12 h of incubation (Table S1).

289 These results show that adaptive evolution employing serial batch transfer under constant

290 limonene challenge was successful for isolating limonene-tolerant phenotypes.

291

292 **Identification of mutations by whole-genome sequencing**

293 Six resistant strains were isolated across the evolutionary time course in order to identify

294 targets for genetic engineering. Mutations were identified by whole-genome re-sequencing

295 and each genome was compared with that of the parental strain, which was also sequenced
296 and contained no mutations. For each evolved strain, we first identified all mutations
297 occurring in coding regions. A summary of the sequencing results are listed in Table S1 and
298 all of the mutations for each strain are listed in Table 1. The selection criteria for mutation
299 calling is described in the Materials and Methods section. All resistant strains had a mutation
300 (Q763L) in *PDR3*, while all strains with maximum fitness scores harbored an INDEL in
301 either *TCB2* (deletion of amino acids 314-316, strain TB302 at 120 generations) or the
302 closely related gene *TCB3* (frameshift at base-pair 2966, resulting in the truncation of the
303 protein to 989 amino acids) (Fig. 1). Considering that all of the other mutations found (Fig. 1
304 and Table 1) varied between each of the evolved strains, we assumed these to be passenger
305 mutations arising from genetic drift and decided to focus our engineering efforts on the *PDR3*
306 and *TCB3* mutations only. The genome data is available for download at
307 <http://pathway.aibn.uq.edu.au/S288c/>.

308

309 **Genomic reconstruction of the limonene-tolerant phenotype**

310 We next constructed single- and double- mutations for *PDR3* (Q763L) and *TCB3* (frame shift
311 989) genes in the parental strain and investigated their relative fitness in a gain-of-function
312 assay. A gain-of-function assay examines if a mutation confers the phenotype by
313 reconstructing the mutation in the parent strain as opposed to evaluating the phenotype by
314 knocking out genes systematically in an evolved strain. While a single base change in
315 *pdr3*^{Q763L} showed no significant improvement in fitness compared to the parental strain, the
316 mutation in *tcb3*¹⁻⁹⁸⁹ (leading to truncated protein tTcb3p¹⁻⁹⁸⁹) increased limonene fitness by
317 9-fold and showed no statistical difference in comparison to the evolved strain (Fig. 2). The
318 double mutant, *pdr3*^{Q763L} and *tcb3*¹⁻⁹⁸⁹, resulted in a relative fitness score of 11.5 ± 0.5 , which
319 is also statistically insignificant compared to the fitness score achieved by the evolved

320 mutants or the single *TCB3* mutant (Fig. 2). The reconstructed double mutant, carrying both
321 the *TCB3* and *TCB2* mutations (*tcb3^{I-989}*, *tcb2^{I-316}*), showed no additional increase in fitness
322 compared to the single tTcb3p^{I-989} mutant (Table S7). This data revealed that the mutation in
323 tTcb3p^{I-989} alone could confer limonene tolerance.

324

325 Given the *TCB3* mutation encoded a truncated version of Tcb3p, we questioned whether this
326 mutation resulted in a nonfunctional protein and asked if limonene resistance was due to
327 effective loss of Tcb3p. A *TCB3* knock-out strain, however, showed no enhanced tolerance
328 and matched that of the S288C fitness ($\Delta tcb3$ in Fig. 2). This demonstrates that, despite
329 encoding a truncated protein, the evolved tTcb3p is a gain-of-function mutation. This result
330 further highlights the advantage of ALE over other approaches, where traditional screening of
331 knock-out libraries would not have identified *TCB3* as a viable target.

332

333 Next, we questioned what the potential biological implications were of truncating Tcb3p.
334 Normally, Tcb3p resides exclusively in the cortical endoplasmic reticulum (cER) tethering
335 the cER to the plasma membrane (PM) (28). It was recently demonstrated, however, that a
336 truncated version of Tcb3p, lacking the C2 lipid binding domains (S288C Tcb3p in Fig. 2b),
337 caused Tcb3p to untether from the PM and co-localize in the perinuclear endoplasmic
338 reticulum (nER) and the cER. We investigated if limonene resistance was associated with this
339 dual localization property. We created a similarly truncated version of Tcb3p at position 531,
340 which resulted in limonene tolerance (*tcb3^{I-531}* in Fig. 2a). This data strongly indicates that
341 the gain of function and observed resistant phenotype may be linked to the ability of tTcb3p
342 to reside in both the cER and nER.

343

344 Alternatively, limonene resistance may also be due to the loss of the tricalbin complex. Tcb2p
345 forms a heterocomplex with Tcb3p (and Tcb1p) by binding to the C-terminal portions of
346 tricalbins 1 and 3 (14). With the C-terminus of Tcb3p absent in both truncated versions
347 (position 989 or 531) we questioned if limonene resistance was associated with the
348 breakdown of the Tcb2p-Tcb3p tricalbin complex. A full knock-out of Tcb2p was effective at
349 increasing limonene resistance (Fitness of $\Delta tcb2 = 7.86 \pm 1.27$ in Fig. 2). In addition to the
350 dual localization property of Tcb3p in the ER, the absence of the tricalbin complex may also
351 contribute to the resistance mechanism.

352

353 **Changes to the cell wall integrity, transcriptome and proteome**

354 We previously demonstrated that limonene damages the cell wall (6). Hence, we explored if
355 the tTcb3p¹⁻⁹⁸⁹ mutation improved the structural integrity of the cell wall during limonene
356 stress. Cell wall integrity was measured using calcofluor white (CFW) which is a
357 fluorochrome that binds to cell wall polysaccharides (33). Cells with damaged walls show
358 increased sensitivity and a higher mean fluorescence intensity (MFI) when stained with CFW
359 (6). Shown in Fig. 3c, $59 \pm 6\%$ of S288C cells showed substantial cell wall damage after
360 limonene exposure. This was a ten-fold increase in number of damaged cells compared to the
361 untreated control ($6 \pm 1\%$ in Fig. 3b). In contrast, the mutant cells harboring the single
362 mutation tTcb3p¹⁻⁹⁸⁹ showed a much smaller increase in cell wall damage after limonene
363 treatment, with a two-fold increase in number of cells damaged ($24 \pm 1\%$ vs. $11 \pm 1\%$, Fig. 3e
364 and f). In addition, loss of cell wall integrity affected cytokinesis and defects in cell
365 separation were found to be higher in S288C treated cells compared to the tTcb3p¹⁻⁹⁸⁹ cells
366 (Fig. S3). These results demonstrate that the tTcb3p¹⁻⁹⁸⁹ protein has the ability to preserve cell
367 wall integrity during limonene treatment.

368

369 In wild-type strains, limonene exposure causes a substantial transcriptional response (6).
370 When challenged with limonene, the total number of differentially expressed genes (29
371 genes; see Table S4) was substantially lower for the *tTcb3p*¹⁻⁹⁸⁹ strain compared to S288C
372 (453 genes reported in (6)). This is partly explained by the large number of regulated genes
373 associated with growth defects in S288C (6). The mutant *tTcb3p*¹⁻⁹⁸⁹ showed very small
374 perturbations to growth when challenged with limonene and thus the smaller gene list was not
375 surprising (Fig. S2). However, roughly 30% of the up-regulated gene list is associated with
376 cell wall repair (Table S4). In yeast, the cell wall signaling pathway (CWI) is responsible for
377 responding to cell wall damage (25). The CWI cascade was highly up-regulated in S288C (6),
378 but was not induced in mutant cells (Fig. 4). In *tTcb3p*¹⁻⁹⁸⁹ cells, limonene stress induced
379 genes associated with cell wall maintenance, which are not part of the CWI signaling
380 pathway. *ECL1*, *SMP1*, *TIR2*, and *YPL277C* were up-regulated in the mutant but not in
381 S288C and only three up-regulated genes were shared between the strains (*YGP1*, *FIT2*,
382 *FIT3*). Several genes involved in iron ion homeostasis were also up-regulated (*SIT1*, *HMX1*,
383 *ARN1*, *FRE5*, *TIS11*). This response was similarly observed for S288C exposed cells (6).
384 Global transcript analysis was also performed in the absence of limonene to investigate
385 expression patterns directly caused by the *TCB3* mutation (*tTcb3p*¹⁻⁹⁸⁹ mutant compared to
386 S288C gene expression). However, no genes were differentially expressed.
387
388 We also characterized the impact *tTcb3p*¹⁻⁹⁸⁹ had directly on cell wall protein abundance
389 during limonene shock. For untreated cells, Ygp1p was the only protein induced in the
390 mutant compared to S288C (Table S5). The cell wall proteins Plb1p, Plb2p, Ecm33p, Tos1p,
391 Cis3p and Uth1p were found to be lower in abundance in the mutant vs. S288C (Table S5).
392 During limonene challenge, cell wall proteins Pbl2p, Cis3p, and Ccw14p were induced in the
393 mutant but absent in the parental strain. Gas3p, Yap7p and Cwp1p were the only common

394 regulated cell wall proteins found during limonene stress (Fig. 4). Taken together, these data
395 demonstrate that both the *TCB3* mutation and limonene affect protein secretion or cell wall
396 biosynthesis, but in different ways. The underlying mechanisms of this, however, remain
397 unresolved.

398

399 **Tolerance towards other terpenes**

400 To test if *tTcb3p*¹⁻⁹⁸⁹ also conferred tolerance towards other terpenes, the tolerance assays
401 were repeated with a range of compounds. Fitness towards β -pinene and myrcene increased
402 significantly (11- and 8-fold, respectively) compared to S288C (Fig. 5) and the reconstructed
403 strain matched or improved the fitness compared to the evolved strain (TB516). The mutant
404 showed no fitness increase for the aromatic monoterpene cymene (Fig. 5) as well as other
405 aromatics (xylene, benzene and styrene in Table S6). A four-fold improvement was observed
406 (Fig. 5) in the tolerance against a terpene jet fuel precursor mixture (AMJ-700t). AMJ-700t
407 contained by volume 50% limonene, 10% cymene and 40% farnesene. After a single
408 hydrogenation step, AMJ-700t can be converted to the paraffin jet fuel mixture AMJ-700
409 (50% limonane, 10% cymene and 40% farnesane), which was successfully used in a
410 demonstration flight during Rio+20 in June 2012 (1).

411

412 **Discussion**

413 Strains with improved fitness towards limonene and other toxic terpenes were identified
414 through adaptive evolution employing serial batch passaging (Fig. 1 and Fig. 5). In typical
415 ALE approaches, the final strain is sequenced and compared against the parent strain (3).
416 Here, we re-sequenced genomes across the evolutionary time course and constructed a
417 spatiotemporal representation of the environmentally selected mutations. This enabled us to
418 more precisely judge which mutations were potentially significant. For example, if TB511

419 was the only final strain sequenced then six potential gene targets would have had to been
420 examined. Alternatively, we captured mutations in *TCB2/3* and *PDR3* that occurred early on
421 in ALE (Fig. 1). When analyzing the final evolved strains (TB511-519) this information was
422 useful in deciphering which genes to focus on for strain development.

423

424 A mutation in the transcriptional activator for the pleiotropic drug resistance network, *PDR3*,
425 for example, was found in every evolved strain (Fig. 1). Up-regulation of ABC transporters
426 during limonene stress has previously been observed, but overexpression of these failed to
427 improve limonene tolerance (20). Similarly, we observed that a genomic reconstruction of the
428 mutation (*pdr3*^{Q763L}) in S288C did not significantly improve fitness (Fig. 2a). The
429 transporters may address low levels of molecular toxicity, while failing to address the major
430 issue of phase toxicity.

431

432 Mutations in tricalbin [TRI (three) CA (calcium) L (lipid) BIN (binding)](14) proteins Tcb2p
433 or Tcb3p were found in all evolved strains with maximum fitness scores (Fig. 1). A mutation
434 in *TCB2* was found early (120 generations, strain TB302 in Fig. 1), while an INDEL causing
435 truncation at position 989 of *TCB3* was found at later points. Genomic reconstruction of *tcb3*-
436 989 in S288C revealed that the limonene resistant phenotype can be achieved by this single
437 point mutation. The correlation of genotype to phenotype is generally a complex problem
438 (15). To our knowledge, no previous report has described a single point mutation that confers
439 tolerance towards toxic next-generation biofuels in yeast.

440

441 While the specific role of the *TCB3* mutation remains unresolved, this work shows that it is
442 involved in preventing cell wall damage. Limonene stress causes reduced cell wall integrity
443 in S288C (Fig. 3c) and strongly induces the cell wall integrity signaling pathway (Fig. 4). In

444 the reconstructed strain, limonene did not severely affect cell wall integrity (Fig. 3f) and there
445 was no activation of CWI signaling during limonene shock (Fig. 4). Limonene caused
446 different and in several instances opposite effects on the cell wall proteome, while fewer
447 genes involved in cell wall maintenance and biogenesis were affected in the tTcb3p¹⁻⁹⁸⁹
448 variant (Fig. 4). The mutation may directly enhance cell wall resilience, e.g., by increasing
449 the degree of crosslinking. For example, Cis3p and Ccw14p serve as structural stabilizers
450 covalently linking cell wall polysaccharides (29, 30) and were upregulated in the mutant but
451 not the S288C (Fig. 4). Enhanced wall protection was evident after investigating budding
452 patterns during limonene stress (Fig. S3).

453 In addition to biofuel applications, this work has revealed new insights into the biological
454 function of tricalbin proteins, which have homologues to synaptotagmins and SNARE
455 proteins in mammalian cells (41). Little is known about the biological function of tricalbins
456 other than that they can tether the ER to the plasma membrane (28, 41). This study links
457 tricalbins to the regulation of cell wall integrity, which has not been previously described.
458 The data also shows that when tricalbins act as a heterodimer compared to a free protein
459 different biological behavior is observed *in vivo*. This work serves as a foundation for future
460 studies to explore the mechanism and functional implications of this distinction between
461 complexed and non-complexed tricalbins.

462

463 Commercial-level biological production of monoterpenes depends on solving the toxicity
464 problem. Currently, monoterpene olefin production in yeast is still in the developmental stage
465 and titers have yet to reach inhibitory levels (60-200 mg/L). As strain engineering will lead to
466 better performing strains, phase toxicity will become a major constraint. Monoterpenes
467 passively diffuse in and out of cells (5, 12), which means that high endogenous cellular
468 production will drive transport to the extracellular environment increasing the solvent phase

469 and enhancing phase toxicity effects. This is the first example of successful engineering of
470 phase tolerance and the first report of a single point mutation that confers tolerance to a range
471 of toxic next-generation biofuels. Given the simplicity of the Tcb3p mutation, our work
472 provides a straightforward strategy that can be tailored to any yeast strain to increase
473 tolerance with direct applications to biocatalysis or biotransformation of toxic alkenes.

474

475 **Acknowledgements:**

476 We thank the Queensland government (National and International Research Alliances
477 Program) for financial support. JOK was financially supported by the Australian Research
478 Council (DE120101549). BLS was financially supported by a National Health and Medical
479 Research Council Career Development Fellowship (APP1031542). We thank the Australian
480 Wine Research Institute (Adelaide, South Australia, Australia) for providing us with the
481 S288C yeast strain. We thank Chris Paddon (Amyris Inc., Emeryville, CA), Amir Feizi and
482 Jens Nielsen (Chalmers University of Technology, Gothenburg, Sweden) for useful
483 discussions, Amelia Tuffley (University of Queensland) for technical assistance with the cell
484 wall extraction and Tim Mercer (Garvin Institute, UNSW, Australia) for reviewing the
485 manuscript. Whole genome re-sequencing was performed by the Queensland Centre for
486 Medical Genomics, (Institute for Molecular Bioscience, University of Queensland, St. Lucia,
487 Queensland 4072, Australia). Transcriptomics was performed at the Ramaciotti Centre for
488 Gene Function Analysis (University of New South Wales, Sydney, Australia). Microscopy
489 was performed at the Australian National Fabrication Facility (ANFF, University of
490 Queensland, St. Lucia, Queensland 4072, Australia).

491

492 **Competing Financial Interests Statement**

493 The authors declare no competing financial interests.

494

495 **References**

- 496 1. **Amyris**. 2012. (Press release) Azul brazilian airlines makes successful demonstration
497 flight with amyris renewable jet fuel produced from sugarcane.
498 [http://www.amyris.com/News/112/Azul-Brazilian-Airlines-makes-Successful-](http://www.amyris.com/News/112/Azul-Brazilian-Airlines-makes-Successful-Demonstration-Flight-with-Amyris-Renewable-Jet-Fuel-produce)
499 [Demonstration-Flight-with-Amyris-Renewable-Jet-Fuel-produce](http://www.amyris.com/News/112/Azul-Brazilian-Airlines-makes-Successful-Demonstration-Flight-with-Amyris-Renewable-Jet-Fuel-produce).
- 500 2. **Atsumi, S., T. Hanai, and J. C. Liao**. 2008. Non-fermentative pathways for
501 synthesis of branched-chain higher alcohols as biofuels. *Nature* **451**:86-89.
- 502 3. **Atsumi, S., T.-Y. Wu, I. M. P. Machado, W.-C. Huang, P.-Y. Chen, M. Pellegrini,**
503 **and J. C. Liao**. 2010. Evolution, genomic analysis, and reconstruction of isobutanol
504 tolerance in *Escherichia coli*. *Mol Syst Biol* **6**.
- 505 4. **Bailey, U. M., M. F. Jamaluddin, and B. L. Schulz**. 2012. Analysis of congenital
506 disorder of glycosylation-Id in a yeast model system shows diverse site-specific
507 under-glycosylation of glycoproteins. *Journal of proteome research* **11**:5376-5383.
- 508 5. **Bishop, J. R., G. Nelson, and J. Lamb**. 1998. Microencapsulation in yeast cells.
509 *Journal of microencapsulation* **15**:761-773.
- 510 6. **Brennan, T. C. R., J. O. Krömer, and L. K. Nielsen**. 2013. Physiological and
511 transcriptional responses of *Saccharomyces cerevisiae* to *d*-limonene show changes to
512 the cell wall but not to the plasma membrane. *Applied and Environmental*
513 *Microbiology* **79**:3590-3600.
- 514 7. **Brennan, T. C. R., C. D. Turner, J. O. Krömer, and L. K. Nielsen**. 2012.
515 Alleviating monoterpene toxicity using a two-phase extractive fermentation for the
516 bioproduction of jet fuel mixtures in *Saccharomyces cerevisiae*. *Biotechnology and*
517 *Bioengineering* **109**:2513-2522.
- 518 8. **Brown, S. D., A. M. Guss, T. V. Karpinets, J. M. Parks, N. Smolin, S. Yang, M.**
519 **L. Land, D. M. Klingeman, A. Bhandiwad, M. Rodriguez, B. Raman, X. Shao, J.**
520 **R. Mielenz, J. C. Smith, M. Keller, and L. R. Lynd**. 2011. Mutant alcohol
521 dehydrogenase leads to improved ethanol tolerance in *Clostridium thermocellum*.
522 *Proceedings of the National Academy of Sciences* **108**:13752-13757.
- 523 9. **Çakar, Z. P., B. Turanlı-Yıldız, C. Alkım, and Ü. Yılmaz**. 2012. Evolutionary
524 engineering of *Saccharomyces cerevisiae* for improved industrially important
525 properties. *FEMS Yeast Research* **12**:171-182.
- 526 10. **Chang, M., and J. Keasling**. 2006. Production of isoprenoid pharmaceuticals by
527 engineered microbes. *Nat Chem Biol* **2**:674 - 681.
- 528 11. **Choi, M., C.-Y. Chang, and V. Olga**. 2013. Protein significance analysis in LC-MS,
529 SRM and DIA for label-free or label-based proteomics experiments;
530 <http://www.bioconductor.org/packages/2.13/bioc/manuals/MSstats/man/MSstats.pdf>.
- 531 12. **Ciamponi, F., C. Duckham, and N. Tirelli**. 2012. Yeast cells as microcapsules.
532 Analytical tools and process variables in the encapsulation of hydrophobes in *S.*
533 *cerevisiae*. *Applied Microbiology and Biotechnology* **95**:1445-1456.
- 534 13. **Cingolani, P., A. Platts, L. L. Wang, M. Coon, N. Tung, L. Wang, S. J. Land, X.**
535 **Lu, and D. M. Ruden**. 2012. A program for annotating and predicting the effects of
536 single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila*
537 *melanogaster* strain w(1118); iso-2; iso-3. *Fly* **6**:80-92.
- 538 14. **Creutz, C. E., S. L. Snyder, and T. A. Schulz**. 2004. Characterization of the yeast
539 tricalbins: membrane-bound multi-C2-domain proteins that form complexes involved
540 in membrane trafficking. *CMLS, Cell. Mol. Life Sci.* **61**:1208-1220.

- 541 15. **Dowell, R. D., O. Ryan, A. Jansen, D. Cheung, S. Agarwala, T. Danford, D. A.**
542 **Bernstein, P. A. Rolfe, L. E. Heisler, B. Chin, C. Nislow, G. Giaever, P. C.**
543 **Phillips, G. R. Fink, D. K. Gifford, and C. Boone.** 2010. Genotype to Phenotype: A
544 Complex Problem. *Science* **328**:469-469.
- 545 16. **Fischer, M. J. C., S. Meyer, P. Claudel, M. Bergdoll, and F. Karst.** 2011.
546 Metabolic engineering of monoterpene synthesis in yeast. *Biotechnology and*
547 *Bioengineering* **108**:1883-1892.
- 548 17. **Giaever, G., A. M. Chu, L. Ni, C. Connelly, L. Riles, S. Veronneau, S. Dow, A.**
549 **Lucau-Danila, K. Anderson, B. Andre, A. P. Arkin, A. Astromoff, M. El-**
550 **Bakkoury, R. Bangham, R. Benito, S. Brachat, S. Campanaro, M. Curtiss, K.**
551 **Davis, A. Deutschbauer, K. D. Entian, P. Flaherty, F. Foury, D. J. Garfinkel, M.**
552 **Gerstein, D. Gotte, U. Guldener, J. H. Hegemann, S. Hempel, Z. Herman, D. F.**
553 **Jaramillo, D. E. Kelly, S. L. Kelly, P. Kotter, D. LaBonte, D. C. Lamb, N. Lan, H.**
554 **Liang, H. Liao, L. Liu, C. Luo, M. Lussier, R. Mao, P. Menard, S. L. Ooi, J. L.**
555 **Revuelta, C. J. Roberts, M. Rose, P. Ross-Macdonald, B. Scherens, G.**
556 **Schimmack, B. Shafer, D. D. Shoemaker, S. Sookhai-Mahadeo, R. K. Storms, J.**
557 **N. Strathern, G. Valle, M. Voet, G. Volckaert, C. Y. Wang, T. R. Ward, J.**
558 **Wilhelmy, E. A. Winzeler, Y. Yang, G. Yen, E. Youngman, K. Yu, H. Bussey, J.**
559 **D. Boeke, M. Snyder, P. Philippsen, R. W. Davis, and M. Johnston.** 2002.
560 Functional profiling of the *Saccharomyces cerevisiae* genome. *Nature* **418**:387-391.
- 561 18. **Gillet, L. C., P. Navarro, S. Tate, H. Rost, N. Selevsek, L. Reiter, R. Bonner, and**
562 **R. Aebersold.** 2012. Targeted data extraction of the MS/MS spectra generated by
563 data-independent acquisition: a new concept for consistent and accurate proteome
564 analysis. *Molecular & cellular proteomics : MCP* **11**:O111 016717.
- 565 19. **Hill, J., E. Nelson, D. Tilman, S. Polasky, and D. Tiffany.** 2006. Environmental,
566 economic, and energetic costs and benefits of biodiesel and ethanol biofuels.
567 *Proceedings of the National Academy of Sciences* **103**:11206-11210.
- 568 20. **Hu, F., J. Liu, G. Du, Z. Hua, J. Zhou, and J. Chen.** 2012. Key cytomembrane
569 ABC transporters of *Saccharomyces cerevisiae* fail to improve the tolerance to *d*-
570 limonene. *Biotechnology Letters* **34**:1505-1509.
- 571 21. **Jantama, K., M. J. Haupt, S. A. Svoronos, X. Zhang, J. C. Moore, K. T.**
572 **Shanmugam, and L. O. Ingram.** 2008. Combining metabolic engineering and
573 metabolic evolution to develop nonrecombinant strains of *Escherichia coli* C that
574 produce succinate and malate. *Biotechnology and Bioengineering* **99**:1140-1153.
- 575 22. **Keasling, J.** 2008. Synthetic biology for synthetic chemistry. *ACS Chem Biol* **3**:64 -
576 76.
- 577 23. **Khor, G. K., and M. H. Uzir.** 2011. *Saccharomyces cerevisiae*: a potential
578 stereospecific reduction tool for biotransformation of mono- and sesquiterpenoids.
579 *Yeast* **28**:93-107.
- 580 24. **Langmead, B., and S. L. Salzberg.** 2012. Fast gapped-read alignment with Bowtie 2.
581 *Nature Methods* **9**:357-U354.
- 582 25. **Levin, D. E.** 2011. Regulation of cell wall biogenesis in *Saccharomyces cerevisiae*:
583 The cell wall integrity signaling pathway. *Genetics* **189**:1145-1175.
- 584 26. **Liu, Y., J. Chen, A. Sethi, Q. K. Li, L. Chen, B. Collins, L. C. Gillet, B.**
585 **Wollscheid, H. Zhang, and R. Aebersold.** 2014. Glycoproteomic analysis of
586 prostate cancer tissues by SWATH mass spectrometry discovers N-acyl ethanolamine
587 acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness.
588 *Molecular & cellular proteomics : MCP* **13**:1753-1768.

- 589 27. **Lücker, J., M. K. El Tamer, W. Schwab, F. W. A. Verstappen, L. H. W. van der**
590 **Plas, H. J. Bouwmeester, and H. A. Verhoeven.** 2002. Monoterpene biosynthesis in
591 lemon (*Citrus limon*). *European Journal of Biochemistry* **269**:3160-3171.
- 592 28. **Manford, Andrew G., Christopher J. Stefan, Helen L. Yuan, Jason A. MacGurn,**
593 **and Scott D. Emr.** 2012. ER-to-Plasma membrane tethering proteins regulate cell
594 signaling and ER morphology. *Developmental Cell* **23**:1129-1140.
- 595 29. **Moukadiri, I., J. Armero, A. Abad, R. Sentandreu, and J. Zueco.** 1997.
596 Identification of a mannoprotein present in the inner layer of the cell wall of
597 *Saccharomyces cerevisiae*. *Journal of Bacteriology* **179**:2154-2162.
- 598 30. **Mrsa, V., M. Ecker, S. Strahl-Bolsinger, M. Nimtz, L. Lehle, and W. Tanner.**
599 1999. Deletion of new covalently linked cell wall glycoproteins alters the
600 electrophoretic mobility of phosphorylated wall components of *Saccharomyces*
601 *cerevisiae*. *Journal of Bacteriology* **181**:3076-3086.
- 602 31. **Otero, J., W. Vongsangnak, M. Asadollahi, R. Olivares-Hernandes, J. Maury, L.**
603 **Farinelli, L. Barlocher, M. Osteras, M. Schalk, A. Clark, and J. Nielsen.** 2010.
604 Whole genome sequencing of *Saccharomyces cerevisiae*: from genotype to phenotype
605 for improved metabolic engineering applications. *Bmc Genomics* **11**:723.
- 606 32. **Portnoy, V. A., D. Bezdan, and K. Zengler.** 2011. Adaptive laboratory evolution --
607 harnessing the power of biology for metabolic engineering. *Current Opinion in*
608 *Biotechnology* **22**:590-594.
- 609 33. **Ram, A. F., and F. M. Klis.** 2006. Identification of fungal cell wall mutants using
610 susceptibility assays based on Calcofluor white and Congo red. *Nature protocols*
611 **1**:2253-2256.
- 612 34. **Renninger, N., and D. McPhee.** 2008. Fuel compositions comprising farnesene and
613 farnesane derivatives and method of making and using same. US patent 0098645.
- 614 35. **Rico, J., E. Pardo, and M. Orejas.** 2010. Enhanced production of a plant
615 monoterpene by overexpression of the 3-hydroxy-3-methylglutaryl coenzyme a
616 reductase catalytic domain in *Saccharomyces cerevisiae*. *Appl. Environ. Microbiol.*
617 **76**:6449-6454.
- 618 36. **Robinson, J. T., H. Thorvaldsdottir, W. Winckler, M. Guttman, E. S. Lander, G.**
619 **Getz, and J. P. Mesirov.** 2011. Integrative genomics viewer. *Nature Biotechnology*
620 **29**:24-26.
- 621 37. **Schulz, B. L., and M. Aebi.** 2009. Analysis of glycosylation site occupancy reveals a
622 role for Ost3p and Ost6p in site-specific *N*-glycosylation efficiency. *Molecular &*
623 *Cellular Proteomics* **8**:357-364.
- 624 38. **Sikkema, J., J. A. de Bont, and B. Poolman.** 1994. Interactions of cyclic
625 hydrocarbons with biological membranes. *The Journal of biological chemistry*
626 **269**:8022-8028.
- 627 39. **Solis-Escalante, D., N. G. A. Kuijpers, N. Bongaerts, I. Bolat, L. Bosman, J. T.**
628 **Pronk, J.-M. Daran, and P. Daran-Lapujade.** 2013. amdSYM, a new dominant
629 recyclable marker cassette for *Saccharomyces cerevisiae*. *FEMS Yeast Research*
630 **13**:126-139.
- 631 40. **Sullivan, M., S. Li, S. Aroney, B. Deng, C. Li, E. Roura, B. Schulz, B. Harcourt,**
632 **J. Forbes, and R. Gilbert.** 2015. A Rapid Extraction Method for Glycogen from
633 Formalin-fixed Liver. *Carbohydrate Polymers* **118**:9-15.
- 634 41. **Toulmay, A., and W. A. Prinz.** 2012. A conserved membrane-binding domain
635 targets proteins to organelle contact sites. *Journal of Cell Science* **125**:49-58.
- 636 42. **Våremo, L., J. Nielsen, and I. Nookaew.** 2013. Enriching the gene set analysis of
637 genome-wide data by incorporating directionality of gene expression and combining
638 statistical hypotheses and methods. *Nucleic Acids Research* **41**:4378-4391.

- 639 43. **Wright, J., E. Bellissimi, E. de Hulster, A. Wagner, J. T. Pronk, and A. J. A. van**
 640 **Maris.** 2011. Batch and continuous culture-based selection strategies for acetic acid
 641 tolerance in xylose-fermenting *Saccharomyces cerevisiae*. FEMS Yeast Research
 642 **11:299-306.**

643

644 Tables:

645 **Table 1. Summary of limonene MICs and mutations found in evolved strains**
 646

Strain	Gen	MIC ^a (mg/l)	FC ^b	Mutation	Gene	Function
S288C	0	69	-	-	-	-
TB302	120	130	1.9	SNP (Q763L)	<i>PDR3</i>	Transcriptional activator of the pleiotropic drug resistance network
				INDEL (deletion E314,V315,P316)	<i>TCB2</i>	ER protein located in the mother and daughter bud, involved in ER-plasma membrane tethering
TB405	160	122	1.8	SNP (Q763L)	<i>PDR3</i>	See above
				INDEL (frame shift 989)	<i>TCB3</i>	ER protein located in the mother and daughter bud, involved in ER-plasma membrane tethering
				INDEL (frame shift 192)	<i>TSA1</i>	Thioredoxin peroxidase
				SNP (Q192G)		
				SNP (D380H)	<i>UBP11</i>	Ubiquitin-specific protease
TB511	200	138	2.0	SNP (Q763L)	<i>PDR3</i>	See above
				INDEL (frame shift 989)	<i>TCB3</i>	See above
				INDEL (frame shift 192),	<i>TSA1</i>	See above
				SNP (Q192G)		

				SNP (W580S)	<i>KSP1</i>	Serine/threonine protein kinase
				SNP (nonsense Q1014*)	<i>PSE1</i>	Karyopherin/importin that interacts with the nuclear pore complex
				SNP (L84S)	<i>RPL30</i>	Ribosomal 60S subunit protein
TB516	200	138	2.0	SNP (Q763L)	<i>PDR3</i>	See above
				INDEL (frame shift 989)	<i>TCB3</i>	See above
				INDEL, SNP (Q192G)	<i>TSA1</i>	See above
				SNP (R159T)	<i>CDC34</i>	Ubiquitin-conjugating enzyme, regulates cell cycle progression by targeting key substrates for degradation
TB517	200	145	2.1	SNP (Q763L)	<i>PDR3</i>	See above
				INDEL (frame shift 989)	<i>TCB3</i>	See above
				SNP (nonsense Q1014*)	<i>PSE1</i>	See above
				SNP (L84S)	<i>RPL30</i>	See above
TB519	200	138	2.0	SNP (Q763L)	<i>PDR3</i>	See above
				INDEL (frame shift 989)	<i>TCB3</i>	See above
				SNP (G826R)	<i>SIP3</i>	Transcription cofactor, acts through interaction with DNA-bound Snf1p
				SNP (L127F)	<i>YMR102</i> <i>c</i>	Protein of unknown function

647 ^a The minimum inhibitory concentration (MIC) is defined as the amount of limonene required to
 648 inhibit the specific growth rate by approximately 50% compared to growth rate with no solvent
 649 present for each strain.

650 ^b Fold change (FC) is the ratio of the MIC for the evolved and S288C strain.

651

652 Figure legends


653 **Figure 1.** Summary of the evolved strains' relative fitness and genetic mutations. Relative
654 fitness is defined as the ratio of the cell density (OD₆₆₀) at 12 and 0 h during limonene
655 exposure (138 mg/l). Error bars represent one SD above the mean for biological replicates (n
656 = 3). The location of each mutation can be found in Table 1.

657
658 **Figure 2. (a)** Relative fitness towards limonene for reconstructed mutations. Relative fitness
659 is defined in Fig 1. The evolved strain score represents the average fitness score for all
660 evolved strains (TB302-519). Beneficial mutations in *PDR3* and *TCB3* were constructed in
661 the parent strain (S288C). Error bars represent one SD above the mean for biological
662 replicates ($n = 3$). Significance was determined by one-way ANOVA to correct for multiple
663 comparisons relative to the S288C (**** $p < 0.001$, ns, not significant; $p > 0.05$). **(b)** Diagram
664 of S288C and mutant tTcb3p¹⁻⁹⁸⁹. The amino acid length is indicated; TMD, transmembrane
665 domain; SMP, synaptotagmin-like-mitochondrial lipid-binding protein; C2, lipid binding
666 domain.


667
668 **Figure 3.** Histograms representing the variation in fluorescence emitted from S288C and
669 tTcb3p¹⁻⁹⁸⁹ mutant cells. **(a and d)** unstained cells; **(b and e)** unexposed control cells stained
670 with calcofluor white (CFW); **(c and f)** cells stained with CFW after 2 h of limonene
671 exposure. The mean fluorescence intensity (MFI) and percentage of damaged cells (Pop %)
672 are reported for biological replicates ($n = 3$, $\pm$ SD).

673
674 **Figure 4.** Cell wall transcriptome and proteome response during limonene stress (+/-
675 limonene treatment). Venn diagram representing overlap and differences in cell wall gene
676 expression (up-regulated genes only) and protein abundance for S288C and tTcb3p¹⁻⁹⁸⁹ cells.
677 Up-regulated cell wall genes from the S288C were used from Brennan et al. (6). Up-regulated

678 genes (mutant) and cell wall proteins (S288C and tTcb3p¹⁻⁹⁸⁹ mutant) were analyzed in this
679 study. Transcriptomic data are italicized genes (e.g., *MTL1*) and proteomic data is represented
680 as unitalicized proteins (e.g., Sag1p).
681
682 **Figure 5.** Relative fitness towards other terpenes. S288C, evolved (TB516), and the
683 reconstructed tTcb3p¹⁻⁹⁸⁹ strains were subjected to relative fitness assays for β -pinene (198
684 mg/l), myrcene (361 mg/l), cymene (140 mg/l) and AMJ-700t (225 mg/l). AMJ-700t contains
685 by volume 10% cymene, 50% limonene, 40% farnesene. Controls represent no exposure.
686 Relative fitness is defined in Fig 1. Error bars represent one SD from the mean for biological
687 replicates ($n = 3$).



a



b

